Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


If States Win Lawsuits Against Health Reform Law, How Might Pharma Fare?

Executive Summary

While it’s likely to be 2012 before a final decision is handed down in lawsuits states have brought challenging the constitutionality of the Patient Protection and Affordable Care Act, questions are already arising about the possible impact on the law's pharmaceutical-related provisions if the states prevail.

You may also be interested in...

Voices From The Bench: Supreme Court Justices Probe The Affordable Care Act

“The Pink Sheet” highlights intriguing, and perhaps telling, comments by U.S. Supreme Court justices from three days of oral arguments pertaining to the constitutionality of the Affordable Care Act, including the constitutionality of the “individual mandate” for insurance coverage, its severability from other ACA provisions, and whether new Medicaid requirements are an unconstitutional coercion of the states.

Supreme Court’s Consideration Of ACA’s “Individual Mandate” Has Three Possible Outcomes

At stake is the requirement for individuals to purchase health insurance and whether that provision is severable from the rest of the Affordable Care Act. From the pharmaceutical industry’s perspective, the most disruptive outcome would be to have the entire law overturned.

Federal Judge's Ruling To "Void" Affordable Care Act Encompasses Entire Reform Law

In Jan. 31 ruling that the individual mandate is unconstitutional, Judge Vinson declines to sever the provision from the remainder of ACA, meaning all pharma-related provisions would be struck down if the ruling stands.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts